India markets open in 32 minutes

Cipla Limited (CIPLA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
767.40-10.25 (-1.32%)
At close: 3:29PM IST
Full screen
Previous close777.65
Bid0.00 x 0
Ask0.00 x 0
Day's range761.80 - 784.00
52-week range355.30 - 819.30
Avg. volume8,041,158
Market cap619.221B
Beta (5Y monthly)0.55
PE ratio (TTM)37.63
EPS (TTM)20.39
Earnings date06-Nov-2020
Forward dividend & yield6.00 (0.77%)
Ex-dividend date19-Mar-2020
1y target est592.05
  • Reuters

    Zydus Cadila launches India's cheapest remdesivir version at $37 per vial

    Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing

  • India's shortage of remdesivir is easing, says producer Cipla

    India's shortage of remdesivir is easing, says producer Cipla

    India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd. Remdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are authorised to make and sell generic versions in 127 developing nations. Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, Cipla's Global Chief Financial Officer, Kedar Upadhye, told Reuters.

  • Cipla gets India approval to sell COVID-19 drug favipiravir

    Cipla gets India approval to sell COVID-19 drug favipiravir

    Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating. The Drug Controller General of India granted Cipla accelerated approval to make and sell favipiravir in an effort to meet the "urgent and unmet" need for COVID-19 treatment options in the country, the company said. Indian drugmakers including Glenmark Pharmaceuticals Ltd are racing to supply generic versions of favipiravir, originally developed by Japan's Fujifilm Holdings Corp as Avigan for treating influenza.